Clicky

Relief Therapeutics Hldg Ag(RLFTY)

Description: Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications is being investigated in two U.S. Phase 2b/3 clinical trials in acute respiratory deficiency due to COVID-19, as well as in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also involved in clinical development of RLF-100 for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.


Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Peptides Peptide Serious Diseases Covid 19 Sarcoidosis Pulmonary Sarcoidosis Relief Therapeutics Acute And Chronic Lung Diseases Acute Respiratory Deficiency Aviptadil

Home Page: www.relieftherapeutics.com

BAtiment F2/F3
Geneva, 1202
Switzerland
Phone: 41 44 723 59 59


Officers

Name Title
Mr. Jack Weinstein M.B.A. Chief Exec. Officer
Mr. Paolo Galfetti COO & Director
Mr. Jeremy Meinen C.P.A. Chief Accounting Officer, CFO & VP of Admin.
Dr. Nermeen Varawalla DPhil, M.B.A., M.D., MBA, Ph.D. Chief Medical Officer
Mr. Marco Marotta Chief Bus. Officer
Mr. Anthony M. Kim Sr. VP & Head of U.S. Commercial Operations
Mr. Christopher Wick Sr. Director & Head of U.S. Sales
Ms. Drew Cronin-Fine Exec. Director & Head of U.S. Marketing
Dr. Serene Forte M.P.H., Ph.D. Sr. VP & Head of Genetic Medicine
Mr. David McCullough Sr. Director & Head of U.S. Market Access

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 1.2475
Trailing PE: 0
Price-to-Book MRQ: 0.7719
Price-to-Sales TTM: 19.4107
IPO Date:
Fiscal Year End: December
Full Time Employees: 10
Back to stocks